26-Aug-2021 | Facts and Factors
According to a Facts & Factors report, the global viral vectors and plasmid DNA manufacturing market was estimated at approximately USD 2,300.8 Million in 2020 and is projected to produce revenue worth approximately USD 4,500 Million by the end of 2026, growing at a CAGR of approximately 17.4% between 2021 and 2026.
The plasma DNA is a lump of DNA materials gained from different tissues and cells, along with that it is a microbial circular, smaller, and extrachromosomal DNA duplicate self-reliantly used in recombinant DNA technology and genetic engineering. The plasma DNA is classified into GMP Grade Plasmid DNA, Non-GMP grade plasmid DNA, and high-quality plasmid DNA. Good quality plasmid DNA is utilized in the GMP-compliant making of recombinant viruses, RNA, antibodies. The viral vector tool is used by molecular biologists to transfer genetic material into cells. The different types of viral vectors can be used to transport nucleic acids into the genetic makeup of cells along with the lentivirus, retrovirus, adenovirus, and herpes simplex virus, and adeno-associated virus. Viruses have developed to progress particular mechanisms that carry their genomes inside the cells they contaminate.
The global viral vectors and plasmid DNA manufacturing market is anticipated to expand at the largest CAGR owing to the rising cases of patients going for gene therapy as it is a foremost sector in medical science that undertakes new treatment improvements for patients with different diseases. The genetically modified treatment has become a capable treatment approach for several diseases, counting specific viral infections and inherited disorders. The high need for plasmid DNA due to the boost in gene therapy growth is likely to enhance the growth of the market.
Furthermore, the constant research activities associated with the viral vector gene therapies, the availability of useful viral vector gene therapies for cancers and rare diseases, and the new approval of various viral vector gene therapies are propelling the market growth. Also, viral vectors such as baculovirus, adenoviruses, herpes simplex viruses, and others result in better applications in new drug development as well as vaccinology.
On the other hand, the key factors limiting the market growth include ethical, regulatory, and scientific challenges regarding gene therapy, manufacturing capacity restrictions, and production challenges concerning to large-scale manufacturing of vectors. On the contrary, the surge in healthcare infrastructure will produce many growth opportunities in the sector, where the demand for viral vectors and plasmid DNA will increase worldwide in the near future.
The geographical split of viral vector and plasmid DNA manufacturing market comprises North America, Europe, Asia-Pacific, the Middle East, and Africa, and Latin America. In terms of region, North America is dominating the global market due to the augmentation of plasmid DNA and the viral vector manufacturing in the United States because of the largest number of generic drugs in the growth phase, which in turn is creating a high requirement for viral vector manufacturing.
Top Market Players
The leading market players are engaged in strengthening external capital to progress their business operations along with enhancing their market revenue growth. Major manufacturers leading in the global market of vectors & plasmid DNA manufacturing include FUJIFILM Diosynth Biotechnologies, Merck KGaA, Thermo Fisher Scientific, Catalent Inc., Cobra Biologics, Wuxi Biologics, WaismanBiomanufacturing, Takara Bio Inc., Genezen laboratories, MiltenyiBiotec GmbH, Batavia Biosciences, BioNTech IMFS GmbH, Virovek Incorporation, SIRION Biotech GmbH, Advanced BioScience, Audentes Therapeutics, BioMarin Pharmaceutical, RegenxBio Inc., YPOSKESI, and Lonza.
Browse the full report “Viral Vectors And Plasmid DNA Manufacturing Market By Product Type (Viral Vectors, Plasma DNA, and Non-Viral DNA Vectors), By Application (Cancer, Inherited Disorder, Infectious Diseases, and Others), and By End-User (DNA Vaccines, Gene Therapy, Immunotherapy, and Others): Global & Regional Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2021–2026” at https://www.fnfresearch.com/viral-vectors-and-plasmid-dna-manufacturing-market
This report segments the Global Vectors & Plasmid DNA Manufacturing Market as follows:
Global Viral Vectors & Plasmid DNA Manufacturing Market: By Product Type
- Viral Vectors
- Plasma DNA
- Non-Viral DNA Vectors
Global Viral Vectors & Plasmid DNA Manufacturing Market: By Application
- Inherited Disorder
- Infectious Diseases
Global Viral Vectors & Plasmid DNA Manufacturing Market: By End-User
- DNA Vaccines
- Gene Therapy
Global Viral Vectors & Plasmid DNA Manufacturing Market: Regional Segmentation Analysis
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
A 2108, Sargam,
Pune 411041, India
Email: [email protected]